Supertramp, besides the obvious show of confidence, which would arise from both the success of the HerVAX trial and the PD1Vax trials.
The really big news here , is that when the Oncologist leading the trial declares a CR , that patient is finished their participation in the trial.
As opposed to overall survival which takes years to measure, a Complete Response will be done in months. The Merck/Pfizer PDL1 drug is currently approved by the FDA. We could see this approved in less than 2 years from now.
IMU is so close to the money here.. All those investors who steered clear of IMU because of the long timeframes for cancer drugs are going to be disappointed.
Merck/Pfizer will want to open more basket trials ASAP, if this trial shows good results early..
This announcement is just so big.
- Forums
- ASX - By Stock
- IMU
- Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-118
-
-
- There are more pages in this discussion • 135 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M |
Open | High | Low | Value | Volume |
5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35252 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.0¢ | 1753430 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 717241 | 0.058 |
8 | 1860543 | 0.057 |
3 | 1067860 | 0.056 |
20 | 2643992 | 0.055 |
6 | 1127777 | 0.054 |
Price($) | Vol. | No. |
---|---|---|
0.060 | 1095176 | 20 |
0.061 | 520305 | 5 |
0.062 | 290000 | 4 |
0.063 | 100000 | 1 |
0.064 | 217000 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
IMU (ASX) Chart |